Muscle genetic defects can lead to impaired movement, respiratory failure, and other severe symptoms. The development of curative therapies is challenging due to the need for the delivery of gene-editing tools into skeletal muscle cells throughout the body. Here, we used muscular fusogens (Myomaker and Myomerger) to engineer muscle-specific virus-like particles (MuVLPs) for the systemic delivery of gene-editing tools. We demonstrated that MuVLPs can be loaded with diverse payloads, including EGFP, Cre and Cas9/sgRNA ribonucleoproteins (Cas9 RNPs), and can be delivered into muscle cells via targeted membrane fusion. Systemic administration of MuVLPs carrying Cas9 RNPs enabled muscle-specific gene editing, which excised the exon containing a premature terminator codon mutation in mice with Duchenne muscular dystrophy. This treatment restored dystrophin expression in various muscle tissues, including the diaphragm, quadriceps, tibialis anterior, gastrocnemius, and triceps. As a result, the treated mice exhibited a significantly increased capacity for exercise and endurance. This study established a platform for precise gene editing in muscle tissues.